Beclazon Eco, 1 piece, 250 mcg/dose, dosed aerosol for inhalation
Before prescribing inhaled drugs, it is necessary to instruct the patient on the rules for their use, ensuring the most complete delivery of the drug to the desired areas of the lungs. The development of oral candidiasis is most likely in patients with high levels of precipitating antibodies in the blood against the Candida
, which indicates a previous fungal infection. After inhalation, you should rinse your mouth and throat with water. To treat candidiasis, topical antifungal drugs can be used while continuing therapy with beclomethasone dipropionate.
If patients take GCS orally, then inhalations are prescribed while taking the previous dose of GCS, and the patients should be in a relatively stable condition. After about 1–2 weeks, the daily dose of oral corticosteroids begins to be gradually reduced. The dose reduction scheme depends on the duration of previous therapy and the size of the initial dose of GCS. Regular use of inhaled GCS allows in most cases to cancel oral GCS (patients who need to take no more than 15 mg of prednisolone can be completely transferred to inhaled therapy), while in the first months after the transition the patient’s condition should be carefully monitored until his pituitary-adrenal the system will not recover sufficiently to provide an adequate response to stressful situations (such as injury, surgery, or infection).
When transferring patients from taking systemic corticosteroids to inhalation therapy, allergic reactions (for example, allergic rhinitis, eczema), which were previously suppressed by systemic drugs, may occur.
Patients with reduced function of the adrenal cortex who are transferred to inhalation treatment should have a supply of GCS and always carry a warning card with them, which should indicate that in stressful situations they need additional systemic administration of GCS (after eliminating the stressful situation, the dose of GCS can be repeated reduce). A sudden and progressive worsening of asthma symptoms is a potentially dangerous condition, often life-threatening for patients, and requires an increase in the dose of GCS. An indirect indicator of the ineffectiveness of therapy is the more frequent use of short-acting β2-agonists than before.
Beclomethasone dipropionate for inhalation is not intended for the relief of attacks, but for regular daily use. To stop attacks, short-acting β2-agonists (for example, salbutamol) are used. In case of severe exacerbation of bronchial asthma or insufficient effectiveness of the therapy, the dose of beclomethasone dipropionate should be increased and, if necessary, a systemic corticosteroid and/or an antibiotic should be prescribed if the infection develops.
If paradoxical bronchospasm develops, you should immediately stop using beclomethasone dipropionate, assess the patient's condition, conduct an examination and, if necessary, prescribe therapy with other drugs. With long-term use of any inhaled corticosteroids, especially in high doses, systemic effects may be observed (see section “Side effects”), but the likelihood of their development is much lower than when taking corticosteroids orally. Therefore, it is especially important that when a therapeutic effect is achieved, the dose of inhaled corticosteroids is reduced to the minimum effective dose that controls the course of the disease. At a dose of 1500 mcg/day, the drugs do not cause significant suppression of adrenal function in most patients. Due to possible adrenal insufficiency, special care should be taken and regular monitoring of adrenal cortex function indicators when transferring patients taking GCS orally to treatment with Beclazone Eco and Beclazone Eco easy breathing.
It is recommended to regularly monitor the growth dynamics of children receiving inhaled corticosteroids for a long time. Abrupt withdrawal of beclomethasone dipropionate inhalations is not recommended.
Particular care should be taken when treating patients with active or inactive forms of pulmonary tuberculosis with inhaled corticosteroids.
It is necessary to protect the eyes from contact with drugs. By washing after inhalation you can prevent damage to the skin of the eyelids and nose.
Medication containers must not be punctured, disassembled or thrown into fire, even if they are empty. Like most other inhalation products in aerosol packages, Beclazon Eco and Beclazon Eco Easy Breathing may be less effective at low temperatures. When cooling the cylinder, it is recommended to remove it from the plastic case and warm it with your hands for several minutes.
Effect on the ability to drive a car/use machines
No data.
Beclazone Eco
Before using Beclazon Eco, you must ensure that the patient is using the inhalation device correctly to ensure sufficient dosage of the drug.
Patients using the drug Beclazon Eco at home should be warned that if the effect of the usual dose becomes less effective or shorter lasting, they should not independently increase the dose or frequency of use of the drug, but should immediately consult a doctor.
With long-term use of beclomethasone in high doses (more than 400 mcg/day), candidiasis of the oral cavity and pharynx develops, especially in patients who have previously had a fungal infection, which is confirmed by the high level of precipitating antibodies against Candida fungi in the blood. As a rule, the use of antifungal drugs helps to quickly eliminate the fungal infection. The dose of beclomethasone in this case should not be changed.
If treatment with inhaled beclomethasone begins while taking oral corticosteroids, then reducing the dose of corticosteroids can begin only 1-2 weeks after the start of simultaneous use. The dose reduction regimen for oral corticosteroids depends on the dose and duration of corticosteroid use. Regular use of inhaled beclomethasone in most cases allows you to reduce the dose of GCS for oral administration. As a rule, patients taking no more than 15 mg of prednisolone can completely switch to taking inhaled beclomethasone only. The first months after switching to inhaled therapy with beclomethasone, it is necessary to carefully monitor the state of the HPA axis to prevent its suppression.
Patients with reduced adrenal function who are completely transferred to treatment with inhaled beclomethasone should always have a supply of GCS with them and carry a warning card with information that in stressful situations they need to use systemic GCS. After the end of the stressful situation, the dose of GCS can be reduced or GCS can be discontinued.
An increase in the dose of GCS is required in case of sudden and progressive worsening of bronchial asthma. An indirect indicator of the ineffectiveness of therapy is the more frequent use of short-acting beta2-agonists.
When transferring patients from oral corticosteroids to inhaled corticosteroids, including beclomethasone, various allergic reactions may occur, including allergic rhinitis and allergic dermatitis, which did not appear during treatment with systemic corticosteroids.
Beclomethasone for inhalation is intended for regular daily use and not for relieving bronchospasm attacks. To relieve bronchospasm attacks, beta2-adronomimetics, including salbutamol, are used. In case of severe bronchial asthma or insufficient effectiveness of inhaled beclomethasone, it is necessary to increase its dose, and also consider the use of corticosteroids orally or, for example, the use of antibiotics in case of infectious inflammation.
If paradoxical bronchospasm develops, beclomethasone should be discontinued, the patient examined and the possibility of using another drug considered.
Do not abruptly stop treatment with inhaled beclomethasone.
With long-term use of inhaled beclomethasone at a dose of more than 1.5 g/day, systemic reactions of various types may develop, including symptoms of suppression of the function of the adrenal cortex, decreased growth rate in children, decreased bone mineral density, cataracts, and glaucoma. Therefore, when a therapeutic effect is achieved, the dose of inhaled beclomethasone should be reduced to the minimum effective dose that controls the course of the disease. Patients at high risk of developing adrenal insufficiency should be under the supervision of a physician.
With long-term use of beclomethasone in children, it is necessary to monitor the dynamics of their growth.
Caution should be exercised when using inhaled GCS in patients with active and inactive forms of pulmonary tuberculosis.
It is necessary to protect your eyes from contact with Beclazon Eco.
The aluminum canister containing Beclazon Eco cannot be pierced, disassembled or heated, even if it is empty.
Beclazon Eco aerosol for inhalation 100 mcg/dose 200 doses in Moscow
inhalation administration only
.
The drugs are used regularly (even in the absence of symptoms of the disease), the dose of beclomethasone dipropionate is selected taking into account the clinical effect in each specific case.
In mild cases of bronchial asthma, the forced expiratory volume (FEV1) or peak expiratory flow (PEF) is more than 80% of the expected values, with a spread of PEF values of less than 20%.
In moderate cases, FEV1 or PEF is 60–80% of the required values, the daily variation in PEF indicators is 20–30%.
In severe cases, FEV1 or PEF is 60% of the required values, the daily spread of PEF indicators is more than 30%.
When switching to a high dose of inhaled beclomethasone dipropionate, many patients receiving systemic corticosteroids will be able to reduce their dose or stop them altogether.
The initial dose of drugs is determined by the severity of bronchial asthma. The daily dose is divided into several doses.
Depending on the patient's individual response, the dose of drugs can be increased until clinical effect appears or reduced to the minimum effective dose.
Adults and children aged 12 years and older
Recommended initial doses of drugs:
— mild bronchial asthma — 200–600 mcg/day;
— moderate bronchial asthma — 600–1000 mcg/day;
- severe bronchial asthma - 1000–2000 mcg/day.
Treatment of bronchial asthma is based on a stepwise approach - therapy begins according to the step corresponding to the severity of the disease. Inhaled corticosteroids are prescribed at the second stage of therapy.
Stage 2.
Basic therapy
Beclomethasone dipropionate 100–400 mcg 2 times a day.
Stage 3.
Basic therapy
Inhaled corticosteroids are used in a high dose or in a standard dose, but in combination with inhaled long-acting β2-adrenergic agonists.
Beclomethasone dipropionate in a high dose of 800–1600 mcg/day, in some cases megadoses up to 2000 mcg/day.
Stage 4.
Severe bronchial asthma
Beclomethasone dipropionate in a high dose of 800–1600 mcg/day, in some cases megadoses up to 2000 mcg/day.
Stage 5.
Severe bronchial asthma
Beclomethasone dipropionate in high dose (see step 3, 4)
Children aged 4 to 12 years
Up to 400 mcg/day in several doses.
Special patient groups
There is no need to adjust the dose of drugs in the elderly or in patients with renal or liver failure.
Skipping one dose of medication
If you accidentally miss an inhalation, the next dose must be taken at the scheduled time in accordance with the treatment regimen.
Preparations containing 250 mcg per dose are not intended for use in pediatrics.
Administration can be carried out using a special optimizer, which improves the distribution of the drug in the lungs and reduces the risk of side effects.
